📋 Tender Overview
Project Number
50061
Company Name
NEOLPHARMA, S.A. DE C.V.
Date SPI Disclosed
Jul 25, 2025
Country
Mexico
Region
Latin America and the Caribbean
Projected Board Date
Aug 29, 2025
Environmental Category
B - Limited
Status
Pending Approval
Last Updated Date
Department
Regional Industry MAS LAC & EUR
Industry
other
Sector
Q-B - Retail
Project Description
Grupo Neolpharma ( Neolpharma or the Group ) is a family-owned pharmaceutical company primarily operating in Mexico. It offers over 250 branded and generic medicines across various therapeutic areas, including central nervous system (CNS) diseases, cardiovascular diseases, oncology, and diabetes.
In 2021, IFC financed Neolpharma’s initial expansion plan, encompassing the construction of a new injectables facility in Mexico City, the expansion of an active pharmaceutical ingredients (APIs) production plant in Ecatepec, Mexico, and other related expenditures (#39128).
IFC is now proposing a new $70 million long-term corporate loan to support Neolpharma’s further expansion plan in Mexico ( the Project ). The Project includes (i) the acquisition, refurbishment, and reactivation of the NeolSym Civac API plant in Morelos ( API Plant ); (ii) the construction of a new injectables facility in Toluca to provide drug manufacturing services for a third party ( CMO Plant ); and (iii) technological upgrades and new equipment for Neolpharma’s existing plants, including the refurbishing of corporate offices.
Associated Advisory Engagement
Neolpharma has engaged with IFC in multiple upstream and advisory services. These include (i) the APIs everywhere project in FY23, aimed at promoting the production of low cost APIs in six pilot countries, including Mexico; (ii) two gender advisory projects, the first, during fiscal years 2022-23, focused on developing an internal gender action plan, and the second, currently underway, focuses on disability inclusion and safe and respectful workplaces; (iii) an assessment of the sustainability strategy and the efficient use of water and energy for the development of a roadmap; (vi) advisory to strengthen Neolpharma’s energy management systems; and (v) carbon footprint advisory, focused on advancing Neolpharma’s decarbonization and sustainability journey.
